TIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor -naïve) aged at least 4 weeks and weighing at least 3 kg.
From the U.S. FDA-approved label for Dolutegravir. Full label: DailyMed.
TIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor -naïve) aged at least 4 weeks and weighing at least 3 kg. TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/ mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent.
From the U.S. FDA-approved label for Dolutegravir. Full label: DailyMed.
May be taken without regard to food. UGT = uridine diphosphate glucuronosyltransferase; CYP = cytochrome P450. a Rilpivirine dose is 25 mg once daily for those switching to dolutegravir plus rilpivirine.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
TIVICAY and TIVICAY PD are contraindicated in patients: with previous hypersensitivity reaction to dolutegravir. receiving dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events. Previous hypersensitivity reaction to dolutegravir. Coadministration with dofetilide.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported. Discontinue TIVICAY or TIVICAY PD and other suspect agents immediately if signs or symptoms of hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening reaction. Hepatotoxicity has been reported in patients receiving dolutegravir-containing regimens. Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations. Monitoring for hepatotoxicity is recommended.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following serious adverse drug reactions are discussed in other sections of the labeling: Hypersensitivity reactions. Hepatotoxicity. Immune Reconstitution Syndrome. The most common adverse reactions of moderate to severe intensity and incidence at least 2% (in those receiving TIVICAY in any one adult trial) are insomnia, fatigue, and headache.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
1 product from 1 maker in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Instgra Tablet | Dolutegravir (50mg) | Emcure Pharmaceuticals Ltd | bottle of 30 tablets |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
Store TIVICAY tablets at 25°C (77°F);
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
